NCT05266846 is a single-arm phase 2 study investigating the use of pembrolizumab, bevacizumab, and chemotherapy in ALK + metastatic NSCLC patients who have progressed through Alectinib with persistent 5′ALK. Here, ALK is linked to non-small cell lung carcinoma.